Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NNC0194-0499 in Japanese and Non-Asian Men
NCT04722653Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2021
- Primary completion
- Apr 2021
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing NNC0194-0499 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Feb 2021; status: completed.
02
Drugs
nn9500
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04722653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722653.